![33964148_28_10_2022_2 [Converted]-01-01.png](https://static.wixstatic.com/media/6ef6c7_5f544a22d3e44e38864a07b9d0a57a38~mv2.png/v1/fill/w_980,h_102,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/6ef6c7_5f544a22d3e44e38864a07b9d0a57a38~mv2.png)
Technology
Our Products
Under previous Phase I and current Phase II SBIR funding from the Defense Health Agency (DHA), Critical Innovations is developing the
Previously funded under Defense Health Agency (DHA) Phase I, Phase II, and Phase IIE SBIR awards, two separate Joint Program Committee
Previously funded under Defense Health Agency (DHA) Phase I and Phase II SBIR funding awards, FY21 DHA J9 Phase II Enhancement/Phase III funding, and
_JPG.jpg)
Under prior funding from the US Army Medical Materiel Development Activity (USAMMDA) through an Other Transaction Agreement with Military
Recipient of the MTEC 2020 Prototype of the Year Award, this program is funded by the U.S. Army Medical Materiel Development Activity (USAMMDA),
Under recent US Space Force Direct-to-Phase II SBIR funding, Critical Innovations is developing the Fully-Qualified Manufacturing™ (FQM™)
Previously funded under Defense Health Agency (DHA) Phase I, Phase II, and Phase IIE SBIR awards, FY18 Joint Warfighter Medical Research Program
Previously funded under Defense Health Agency (DHA) Direct-to-Phase II, Phase II Enhancement, and Sequential Phase II SBIR awards, and currently funded under
Under previous Phase I and II SBIR awards from the US Army, Sequential Phase II SBIR funding from the Defense Health Agency (DHA), and a current
Funded by the JPC-2/Military Infectious Diseases Research Program through an Other Transaction Agreement with Military Technology Enterprise
Previously funded under Chemical and Biological Defense Program (CBDP) Phase I and Phase II SBIR awards, Critical Innovations has been developing
Under current funding from the Defense Advanced Research Projects Agency (DARPA), Critical Innovations is developing its novel Revite™ Automated
Critical Innovations has been developing this innovative technology under previous Defense Health Agency (DHA) Phase I and Phase II SBIR funding
Under current funding from the United States Army Medical Research and Development Command (USAMRDC) through an Other Transaction
- CAUTION -
All medical technologies listed on this page are INVESTIGATIONAL and NOT AVAILABLE FOR COMMERCIAL SALE. These statements have NOT been evaluated by the Food and Drug Administration and these technologies are NOT currently approved for human use.
CD010 Rev.T 2026-10-06